首页 > 最新文献

Urologie最新文献

英文 中文
[Follow-up after urinary diversion]. [尿路改道后的随访]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-01 DOI: 10.1007/s00120-024-02401-8
Christopher Netsch, Simon Filmar, Sophia Hook, Clemens Rosenbaum, Andreas J Gross, Benedikt Becker

Radical cystectomy is currently the standard of care for muscle-invasive bladder cancer. Different parts of the small and large intestines can be utilized for continent and incontinent urinary diversion. The postoperative follow-up after urinary diversion should consider functional, metabolic and oncological aspects. The functional follow-up of (continent) urinary diversion includes stenosis, emptying disorders or incontinence. The oncological follow-up should focus on the detection of local, urethral and upper tract recurrences as well as distant metastases. As 90% of the tumor recurrences occur during the first 3 years, a close follow-up should be carried out during this period. Metabolic disturbances, such as vitamin B12 and bile acid deficits, acidosis and disorders of calcium metabolism can also occur during long-term follow-up. The metabolic follow-up should consider the metabolic consequences of the parts of the intestines utilized for the urinary diversion.

根治性膀胱切除术是目前治疗肌肉浸润性膀胱癌的标准方法。小肠和大肠的不同部位可用于失禁和失禁尿流改道术。尿路转流术后的随访应考虑功能、代谢和肿瘤等方面。功能性尿路转流术后随访包括尿路狭窄、排空障碍或尿失禁。肿瘤学随访应侧重于检测局部、尿道和上尿道复发以及远处转移。由于 90% 的肿瘤复发发生在头 3 年,因此在此期间应进行密切随访。长期随访期间也可能出现代谢紊乱,如维生素 B12 和胆汁酸缺乏、酸中毒和钙代谢紊乱。代谢方面的随访应考虑到尿路改道所使用的肠道部分的代谢后果。
{"title":"[Follow-up after urinary diversion].","authors":"Christopher Netsch, Simon Filmar, Sophia Hook, Clemens Rosenbaum, Andreas J Gross, Benedikt Becker","doi":"10.1007/s00120-024-02401-8","DOIUrl":"10.1007/s00120-024-02401-8","url":null,"abstract":"<p><p>Radical cystectomy is currently the standard of care for muscle-invasive bladder cancer. Different parts of the small and large intestines can be utilized for continent and incontinent urinary diversion. The postoperative follow-up after urinary diversion should consider functional, metabolic and oncological aspects. The functional follow-up of (continent) urinary diversion includes stenosis, emptying disorders or incontinence. The oncological follow-up should focus on the detection of local, urethral and upper tract recurrences as well as distant metastases. As 90% of the tumor recurrences occur during the first 3 years, a close follow-up should be carried out during this period. Metabolic disturbances, such as vitamin B12 and bile acid deficits, acidosis and disorders of calcium metabolism can also occur during long-term follow-up. The metabolic follow-up should consider the metabolic consequences of the parts of the intestines utilized for the urinary diversion.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1050-1059"},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New therapeutic approaches for non-muscle invasive bladder cancer-is organ preservation also possible after BCG (Bacillus Calmette Guérin)?] [非肌层浸润性膀胱癌的新治疗方法--卡介苗(BCG)后是否也能保留器官?]
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-23 DOI: 10.1007/s00120-024-02417-0
Thorsten H Ecke, Georgios Gakis

Bacillus Calmette-Guérin (BCG) therapy is the standard of care in the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). In the absence of a response to BCG and persistent high-grade disease, cystectomy is recommended depending on the clinical risk. A variety of targeted therapy approaches, which aim at immune- and gene-based molecular targets, such as PD-(L)1 and FGFR, are currently being investigated in randomized studies for BCG-unresponsive NMIBC. Furthermore, novel forms of application for instillation therapy, such as the TAR device, in combination with gemcitabine or erdafitinib are being investigated in clinical trials in order to extend the duration of action of the active substance on the urothelium. Thus, there are now many developments that could make bladder-preserving therapy with comparable survival data possible as an alternative to BCG or in the event of BCG failure. In the future, it will be necessary to clarify how BCG response can be predicted by using molecular markers and how to define risk groups that should primarily be given an alternative therapy to BCG.

卡介苗(BCG)疗法是治疗高风险非肌层浸润性膀胱癌(NMIBC)的标准疗法。如果对卡介苗治疗无反应,且持续存在高级别疾病,则建议根据临床风险进行膀胱切除术。针对免疫和基因分子靶点(如 PD-(L)1 和表皮生长因子受体)的各种靶向治疗方法,目前正在针对卡介苗无反应的 NMIBC 进行随机研究。此外,为了延长活性物质对尿路上皮细胞的作用时间,临床试验正在研究灌注疗法的新型应用形式,如 TAR 装置与吉西他滨或厄达菲替尼的组合。因此,现在有许多新进展,可以使保留膀胱的治疗具有可比的生存数据,从而替代卡介苗或在卡介苗治疗失败的情况下使用。今后,有必要明确如何利用分子标记预测卡介苗反应,以及如何界定应主要采用卡介苗替代疗法的高危人群。
{"title":"[New therapeutic approaches for non-muscle invasive bladder cancer-is organ preservation also possible after BCG (Bacillus Calmette Guérin)?]","authors":"Thorsten H Ecke, Georgios Gakis","doi":"10.1007/s00120-024-02417-0","DOIUrl":"10.1007/s00120-024-02417-0","url":null,"abstract":"<p><p>Bacillus Calmette-Guérin (BCG) therapy is the standard of care in the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). In the absence of a response to BCG and persistent high-grade disease, cystectomy is recommended depending on the clinical risk. A variety of targeted therapy approaches, which aim at immune- and gene-based molecular targets, such as PD-(L)1 and FGFR, are currently being investigated in randomized studies for BCG-unresponsive NMIBC. Furthermore, novel forms of application for instillation therapy, such as the TAR device, in combination with gemcitabine or erdafitinib are being investigated in clinical trials in order to extend the duration of action of the active substance on the urothelium. Thus, there are now many developments that could make bladder-preserving therapy with comparable survival data possible as an alternative to BCG or in the event of BCG failure. In the future, it will be necessary to clarify how BCG response can be predicted by using molecular markers and how to define risk groups that should primarily be given an alternative therapy to BCG.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"977-984"},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The metastatic and advanced upper tract urothelial carcinoma-a separate entity or bladder cancer's younger sibling?] [转移性和晚期上尿路上皮癌--独立实体还是膀胱癌的弟弟妹妹?]
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-10-01 Epub Date: 2024-09-02 DOI: 10.1007/s00120-024-02421-4
M Haas, V Bahlinger, M Burger, C Bolenz, Y Ma

Upper tract urothelial carcinoma (UTUC) is a cancer that is often already in an advanced stage at the time of initial diagnosis. Although urothelial carcinoma of the upper and lower urinary tracts both originate from the urothelium and have similar genetic alterations, there are significant differences in their distribution. In localized high-risk UTUC, radical nephroureterectomy is the gold standard therapy. In metastatic UTUC, major changes are emerging in sequential therapy due to the investigation of new classes of drugs. In addition to platinum-based combination chemotherapy and immunotherapy, new substances such as antibody-drug conjugates (ADCs) and FGFR inhibitors are used.

上尿路尿路上皮癌(UTUC)是一种在初次诊断时通常已处于晚期的癌症。虽然上尿路和下尿路尿路上皮癌都起源于尿路上皮,并有相似的基因改变,但其分布却有显著差异。对于局部高危UTUC,根治性肾切除术是金标准疗法。对于转移性UTUC,由于新药种类的研究,序贯疗法正在发生重大变化。除了以铂为基础的联合化疗和免疫疗法外,抗体药物共轭物(ADC)和表皮生长因子受体抑制剂等新物质也得到了应用。
{"title":"[The metastatic and advanced upper tract urothelial carcinoma-a separate entity or bladder cancer's younger sibling?]","authors":"M Haas, V Bahlinger, M Burger, C Bolenz, Y Ma","doi":"10.1007/s00120-024-02421-4","DOIUrl":"10.1007/s00120-024-02421-4","url":null,"abstract":"<p><p>Upper tract urothelial carcinoma (UTUC) is a cancer that is often already in an advanced stage at the time of initial diagnosis. Although urothelial carcinoma of the upper and lower urinary tracts both originate from the urothelium and have similar genetic alterations, there are significant differences in their distribution. In localized high-risk UTUC, radical nephroureterectomy is the gold standard therapy. In metastatic UTUC, major changes are emerging in sequential therapy due to the investigation of new classes of drugs. In addition to platinum-based combination chemotherapy and immunotherapy, new substances such as antibody-drug conjugates (ADCs) and FGFR inhibitors are used.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1011-1018"},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Balancing family and career for female physicians in Germany: insights from a survey of female urologists]. [德国女医生兼顾家庭与事业:泌尿科女医生调查的启示]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-09-16 DOI: 10.1007/s00120-024-02439-8
Laura Wiemer, Sophie Knipper, Annika Herlemann, Maria-Noemi Welte, Carolin Siech, Eva-Maria Greiser, Karina Müller, Laura Bellut, Sandra Schönburg, Margarete Walach, Raisa Pompe, Sarah Weinberger

Background: The shortage of skilled labor in medicine is one of the most pressing challenges in healthcare. The increasing number of women in medicine, particularly in the field of urology, raises questions about the compatibility of family and career, especially concerning the work environment and working time models.

Objective: The aim of this study is to capture the impact of motherhood on the professional lives of female physicians and scientists in the field of urology in Germany. Specific challenges in this surgical specialty and the compatibility of family and career will be highlighted.

Methods: The working group "Female Physicians and Scientists in Urology" of the German Society of Urology (DGU) surveyed its 1343 female members regarding demographic data, professional status, and aspects of work-life balance.

Results: Among 487 female urologists in Germany, 53.4% had children. Mothers tended to be older, less frequently in training, less often in inpatient settings, and less frequently engaged in surgical activities. Notably, the proportion of full-time working mothers (36.2%) was significantly lower compared to female urologists without children (92.4%). Among female urologists with children, 32.3% reported having changed their workplace because of their children, while 10.7% indicated that their responsibilities had changed at least once after pregnancy. Additionally, 76.9% of mothers had reduced their weekly working hours due to family commitments. Multivariate analysis showed an influence of motherhood on professional status and parttime work.

Conclusion: The fact that starting a family for women in urology in Germany is associated with a reduction in working hours and the end of clinical careers suggests a need for optimizing the compatibility of family and career in Germany. The increasing feminization of the medical profession exacerbates the existing shortage of skilled workers due to the exit of mothers from professional life. To meet the needs of working parents, particularly mothers, urgent adjustments in the work environment are necessary. Promoting flexible working time models and creating supportive conditions are crucial to preventing the loss of skilled professionals and maintaining job satisfaction in this field.

背景:医学领域熟练劳动力的短缺是医疗保健领域最紧迫的挑战之一。越来越多的女性从医,尤其是在泌尿外科领域,引发了家庭与事业兼顾的问题,特别是在工作环境和工作时间模式方面:本研究旨在了解在德国泌尿外科领域,母亲身份对女医生和女科学家职业生活的影响。研究方法:方法:德国泌尿外科学会(DGU)的 "泌尿外科女医生和女科学家 "工作组对其 1343 名女会员进行了调查,内容涉及人口统计学数据、职业状况以及工作与生活平衡的各个方面:在德国的 487 名泌尿科女医生中,53.4% 有子女。母亲往往年龄较大,较少接受培训,较少住院治疗,较少参与手术活动。值得注意的是,与无子女的泌尿科女医生(92.4%)相比,全职母亲的比例(36.2%)明显较低。在有孩子的女性泌尿科医生中,32.3%的人表示曾因孩子而改变工作场所,10.7%的人表示怀孕后至少改变过一次工作职责。此外,76.9%的母亲因家庭负担而减少了每周的工作时间。多变量分析表明,母亲身份对职业地位和兼职工作有影响:结论:德国泌尿科女性成家与工作时间减少和临床职业生涯结束有关,这表明德国有必要优化家庭与职业的兼容性。由于母亲退出职业生活,医疗行业的女性化日益加剧,加剧了现有技术工人的短缺。为了满足职业父母,尤其是母亲的需求,必须对工作环境进行紧急调整。推广灵活的工作时间模式和创造有利条件,对于防止该领域专业技术人员的流失和保持工作满意度至关重要。
{"title":"[Balancing family and career for female physicians in Germany: insights from a survey of female urologists].","authors":"Laura Wiemer, Sophie Knipper, Annika Herlemann, Maria-Noemi Welte, Carolin Siech, Eva-Maria Greiser, Karina Müller, Laura Bellut, Sandra Schönburg, Margarete Walach, Raisa Pompe, Sarah Weinberger","doi":"10.1007/s00120-024-02439-8","DOIUrl":"https://doi.org/10.1007/s00120-024-02439-8","url":null,"abstract":"<p><strong>Background: </strong>The shortage of skilled labor in medicine is one of the most pressing challenges in healthcare. The increasing number of women in medicine, particularly in the field of urology, raises questions about the compatibility of family and career, especially concerning the work environment and working time models.</p><p><strong>Objective: </strong>The aim of this study is to capture the impact of motherhood on the professional lives of female physicians and scientists in the field of urology in Germany. Specific challenges in this surgical specialty and the compatibility of family and career will be highlighted.</p><p><strong>Methods: </strong>The working group \"Female Physicians and Scientists in Urology\" of the German Society of Urology (DGU) surveyed its 1343 female members regarding demographic data, professional status, and aspects of work-life balance.</p><p><strong>Results: </strong>Among 487 female urologists in Germany, 53.4% had children. Mothers tended to be older, less frequently in training, less often in inpatient settings, and less frequently engaged in surgical activities. Notably, the proportion of full-time working mothers (36.2%) was significantly lower compared to female urologists without children (92.4%). Among female urologists with children, 32.3% reported having changed their workplace because of their children, while 10.7% indicated that their responsibilities had changed at least once after pregnancy. Additionally, 76.9% of mothers had reduced their weekly working hours due to family commitments. Multivariate analysis showed an influence of motherhood on professional status and parttime work.</p><p><strong>Conclusion: </strong>The fact that starting a family for women in urology in Germany is associated with a reduction in working hours and the end of clinical careers suggests a need for optimizing the compatibility of family and career in Germany. The increasing feminization of the medical profession exacerbates the existing shortage of skilled workers due to the exit of mothers from professional life. To meet the needs of working parents, particularly mothers, urgent adjustments in the work environment are necessary. Promoting flexible working time models and creating supportive conditions are crucial to preventing the loss of skilled professionals and maintaining job satisfaction in this field.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Organ-preserving treatment for urothelial carcinoma of the upper urinary tract]. [上尿路尿路上皮癌的保留器官治疗]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-09-13 DOI: 10.1007/s00120-024-02422-3
Clemens M Rosenbaum, Christopher Netsch, Simon Filmar, Sophia Hook, Andreas J Gross, Benedikt Becker

Urothelial carcinoma of the upper urinary tract is rare but the incidence is currently increasing in western countries. Radical nephroureterectomy has long been the standard treatment; however, it can lead to chronic kidney failure and also the necessity for dialysis. Therefore, organ-preserving treatment is now recommended for selected patients with low-risk tumors. The choice of treatment depends on the tumor characteristics, comorbidities and individual risk factors. Surgical options for organ preservation include ureterorenoscopy (URS), percutaneous treatment and partial ureteral resection. The URS is the most frequently used method for organ preservation. Photodynamic diagnostics (PDD) and narrow band imaging (NBI) can potentially also be used for tumor detection in the upper urinary tract. Conservative options such as topical treatment with mitomycin C or Bacillus Calmette-Guérin (BCG) and systemic treatment options are also possible.

上尿路尿路上皮癌虽然罕见,但目前在西方国家的发病率却在不断上升。长期以来,根治性肾切除术一直是标准治疗方法,但它可能导致慢性肾功能衰竭,还必须进行透析。因此,目前建议对部分低风险肿瘤患者进行器官保留治疗。治疗方法的选择取决于肿瘤特征、合并症和个体风险因素。保留器官的手术选择包括输尿管镜检查(URS)、经皮治疗和输尿管部分切除术。输尿管镜检查是最常用的器官保留方法。光动力诊断(PDD)和窄带成像(NBI)也可用于上尿路肿瘤的检测。此外,还可以采用丝裂霉素 C 或卡介苗(BCG)局部治疗等保守治疗方案和全身治疗方案。
{"title":"[Organ-preserving treatment for urothelial carcinoma of the upper urinary tract].","authors":"Clemens M Rosenbaum, Christopher Netsch, Simon Filmar, Sophia Hook, Andreas J Gross, Benedikt Becker","doi":"10.1007/s00120-024-02422-3","DOIUrl":"https://doi.org/10.1007/s00120-024-02422-3","url":null,"abstract":"<p><p>Urothelial carcinoma of the upper urinary tract is rare but the incidence is currently increasing in western countries. Radical nephroureterectomy has long been the standard treatment; however, it can lead to chronic kidney failure and also the necessity for dialysis. Therefore, organ-preserving treatment is now recommended for selected patients with low-risk tumors. The choice of treatment depends on the tumor characteristics, comorbidities and individual risk factors. Surgical options for organ preservation include ureterorenoscopy (URS), percutaneous treatment and partial ureteral resection. The URS is the most frequently used method for organ preservation. Photodynamic diagnostics (PDD) and narrow band imaging (NBI) can potentially also be used for tumor detection in the upper urinary tract. Conservative options such as topical treatment with mitomycin C or Bacillus Calmette-Guérin (BCG) and systemic treatment options are also possible.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Succession of editors-in-chief]. [主编的继任]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-23 DOI: 10.1007/s00120-024-02400-9
Axel Heidenreich, Heiko Wunderlich
{"title":"[Succession of editors-in-chief].","authors":"Axel Heidenreich, Heiko Wunderlich","doi":"10.1007/s00120-024-02400-9","DOIUrl":"https://doi.org/10.1007/s00120-024-02400-9","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 9","pages":"845-847"},"PeriodicalIF":0.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Selection procedure for scientific contributions to the 2024 DGU congress]. [2024 年大会科学贡献评选程序]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-23 DOI: 10.1007/s00120-024-02424-1
Valentin H Meissner
{"title":"[Selection procedure for scientific contributions to the 2024 DGU congress].","authors":"Valentin H Meissner","doi":"10.1007/s00120-024-02424-1","DOIUrl":"https://doi.org/10.1007/s00120-024-02424-1","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 Suppl 2","pages":"25-26"},"PeriodicalIF":0.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Urogeriatric thinking using the example of antiandrogen therapy for prostate cancer]. [以前列腺癌的抗雄激素治疗为例进行老年泌尿系统思考]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-07 DOI: 10.1007/s00120-024-02397-1
A Wiedemann, A Manseck, J Stein, M Fröhner, C Fiebig, A Piotrowski, R Kirschner-Hermanns

The geriatric patient is defined by an age of over 75 years and multimorbidity or by an age of over 80 years. These patients exhibit a particular vulnerability, which, in the incidence of side effects or complications, leads to a loss of autonomy. Treatment sequalae, once they have arisen, can no longer be compensated. It is important to recognize and document treatment requirements among geriatric patients with the help of screening instruments such as the Identification of Seniors at Risk (ISAR) and Geriatric 8 (G8) scores. If a treatment requirement is identified, oncologic treatment should not be commenced uncritically but rather a focus placed on identification of functional deficits relevant to treatment, ideally using a geriatric assessment but at least based on a detailed medical history. These deficits can then be presented in a structured, examiner-independent, and forensically validated manner using special assessments. A planned treatment requires not only consideration of survival gains, but also knowledge of specific side effects and, in geriatric patients in particular, their impact on everyday life. These considerations should be compared with the patient's individual risk profile in order to prevent side effects from negating the effect of the treatment, for example by worsening the patient's self-help status. With regard to androgen deprivation in prostate cancer-which often is used uncritically-it is important to consider possible side effects such as osteoporosis, sarcopenia, anemia, and cognitive impairment in terms of a possible fall risk; an increase in cardiovascular mortality and the triggering of a metabolic syndrome on the basis of preexisting cardiac diseases or risk constellations; and to carry out a careful risk-benefit analysis.

老年病人的定义是年龄超过 75 岁且患有多种疾病或年龄超过 80 岁。这些病人表现出一种特殊的脆弱性,一旦出现副作用或并发症,就会丧失自主能力。治疗后遗症一旦出现,就再也无法弥补。重要的是,要借助筛查工具,如 "高危老年人识别"(ISAR)和 "老年医学 8"(G8)评分,识别并记录老年患者的治疗需求。如果确定有治疗需求,则不应不加批判地开始肿瘤治疗,而应将重点放在确定与治疗相关的功能缺陷上,最好使用老年病学评估,但至少应基于详细的病史。然后,这些缺陷可以通过特殊评估以结构化、独立于检查者和法医验证的方式呈现出来。有计划的治疗不仅需要考虑生存率,还需要了解具体的副作用,尤其是对老年病人而言,还要了解副作用对日常生活的影响。应将这些考虑因素与患者的个人风险状况进行比较,以防止副作用抵消治疗效果,例如恶化患者的自助状态。关于前列腺癌的雄激素剥夺治疗--往往被不加批判地使用--重要的是要考虑可能出现的副作用,如骨质疏松症、肌肉疏松症、贫血和认知功能障碍,以防可能出现的跌倒风险;心血管死亡率的增加,以及在已有心脏疾病或风险组合的基础上引发代谢综合征;并进行仔细的风险-效益分析。
{"title":"[Urogeriatric thinking using the example of antiandrogen therapy for prostate cancer].","authors":"A Wiedemann, A Manseck, J Stein, M Fröhner, C Fiebig, A Piotrowski, R Kirschner-Hermanns","doi":"10.1007/s00120-024-02397-1","DOIUrl":"10.1007/s00120-024-02397-1","url":null,"abstract":"<p><p>The geriatric patient is defined by an age of over 75 years and multimorbidity or by an age of over 80 years. These patients exhibit a particular vulnerability, which, in the incidence of side effects or complications, leads to a loss of autonomy. Treatment sequalae, once they have arisen, can no longer be compensated. It is important to recognize and document treatment requirements among geriatric patients with the help of screening instruments such as the Identification of Seniors at Risk (ISAR) and Geriatric 8 (G8) scores. If a treatment requirement is identified, oncologic treatment should not be commenced uncritically but rather a focus placed on identification of functional deficits relevant to treatment, ideally using a geriatric assessment but at least based on a detailed medical history. These deficits can then be presented in a structured, examiner-independent, and forensically validated manner using special assessments. A planned treatment requires not only consideration of survival gains, but also knowledge of specific side effects and, in geriatric patients in particular, their impact on everyday life. These considerations should be compared with the patient's individual risk profile in order to prevent side effects from negating the effect of the treatment, for example by worsening the patient's self-help status. With regard to androgen deprivation in prostate cancer-which often is used uncritically-it is important to consider possible side effects such as osteoporosis, sarcopenia, anemia, and cognitive impairment in terms of a possible fall risk; an increase in cardiovascular mortality and the triggering of a metabolic syndrome on the basis of preexisting cardiac diseases or risk constellations; and to carry out a careful risk-benefit analysis.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"867-877"},"PeriodicalIF":0.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The new Research Fellowships of the German Society of Urology (DGU) 2023/2024]. [德国泌尿外科学会(DGU)2023/2024 年新研究奖学金]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-20 DOI: 10.1007/s00120-024-02415-2
C Becker
{"title":"[The new Research Fellowships of the German Society of Urology (DGU) 2023/2024].","authors":"C Becker","doi":"10.1007/s00120-024-02415-2","DOIUrl":"10.1007/s00120-024-02415-2","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"917-923"},"PeriodicalIF":0.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Risk-adapted early detection program for prostate cancer 2.0-position paper of the German Society of Urology 2024]. [前列腺癌风险适应性早期检测计划 2.0--德国泌尿外科学会 2024 年立场文件]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-12 DOI: 10.1007/s00120-024-02437-w
Maurice Stephan Michel, Jürgen E Gschwend, Bernd Wullich, Susanne Krege, Christian Bolenz, Axel S Merseburger, Laura-Maria Krabbe, Daniela Schultz-Lampel, Frank König, Axel Haferkamp, Boris Hadaschik

Background and objective: Despite the proven effectiveness of organized PSA-based screening in reducing prostate cancer-related mortality, there is currently no program in Germany covered by statutory health insurance. In accordance with the EU Council Decision (2022/0290(NLE)), the German Society of Urology (DGU) has developed a concept for risk-adapted prostate cancer early detection.

Materials and methods: Based on a literature review of current screening studies, an algorithm for PSA-based prostate cancer early detection was developed.

Results: Risk-adapted prostate cancer screening involves PSA testing in the age group of 45-70 years, followed by PSA-based individual risk stratification and stepwise expansion of diagnostics through magnetic resonance imaging (MRI) to biopsy. While initially up to 2.6 million men will undergo PSA testing, a reduction in these initial examinations to fewer than 200,000 men per year will occur from year four onwards.

Conclusions: The presented algorithm provides clear recommendations for risk-adapted PSA-based early detection for prostate cancer for urologists and patients. The goal is to improve diagnosis of clinically significant prostate cancer, while reducing overdiagnosis and overtreatment.

背景和目的:尽管基于 PSA 的有组织筛查在降低前列腺癌相关死亡率方面效果显著,但德国目前还没有法定医疗保险覆盖的项目。根据欧盟理事会决定(2022/0290(NLE)),德国泌尿外科学会(DGU)提出了一种风险适应性前列腺癌早期检测概念:根据对当前筛查研究的文献回顾,制定了基于 PSA 的前列腺癌早期检测算法:结果:风险适应性前列腺癌筛查包括在 45-70 岁年龄组进行 PSA 检测,然后根据 PSA 进行个体风险分层,并通过磁共振成像(MRI)和活检逐步扩大诊断范围。虽然最初将有多达 260 万名男性接受 PSA 检测,但从第四年开始,最初的检测人数将减少到每年少于 20 万名男性:本文提出的算法为泌尿科医生和患者提供了基于 PSA 的前列腺癌风险适应性早期检测的明确建议。其目的是改善对有临床意义的前列腺癌的诊断,同时减少过度诊断和过度治疗。
{"title":"[Risk-adapted early detection program for prostate cancer 2.0-position paper of the German Society of Urology 2024].","authors":"Maurice Stephan Michel, Jürgen E Gschwend, Bernd Wullich, Susanne Krege, Christian Bolenz, Axel S Merseburger, Laura-Maria Krabbe, Daniela Schultz-Lampel, Frank König, Axel Haferkamp, Boris Hadaschik","doi":"10.1007/s00120-024-02437-w","DOIUrl":"10.1007/s00120-024-02437-w","url":null,"abstract":"<p><strong>Background and objective: </strong>Despite the proven effectiveness of organized PSA-based screening in reducing prostate cancer-related mortality, there is currently no program in Germany covered by statutory health insurance. In accordance with the EU Council Decision (2022/0290(NLE)), the German Society of Urology (DGU) has developed a concept for risk-adapted prostate cancer early detection.</p><p><strong>Materials and methods: </strong>Based on a literature review of current screening studies, an algorithm for PSA-based prostate cancer early detection was developed.</p><p><strong>Results: </strong>Risk-adapted prostate cancer screening involves PSA testing in the age group of 45-70 years, followed by PSA-based individual risk stratification and stepwise expansion of diagnostics through magnetic resonance imaging (MRI) to biopsy. While initially up to 2.6 million men will undergo PSA testing, a reduction in these initial examinations to fewer than 200,000 men per year will occur from year four onwards.</p><p><strong>Conclusions: </strong>The presented algorithm provides clear recommendations for risk-adapted PSA-based early detection for prostate cancer for urologists and patients. The goal is to improve diagnosis of clinically significant prostate cancer, while reducing overdiagnosis and overtreatment.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"893-898"},"PeriodicalIF":0.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Urologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1